Reconsidering the Diagnosis: Abnormal Sweat Chloride Tests in Non‐CF Bronchiectasis
Authors:
Open Access
- 7 January 2025
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (1) , e27471
Abstract
Introduction: While the diagnosis of cystic fibrosis (CF) is often straightforward and reliant on correlation between genetic testing and clinical signs and symptoms, there is a subset where the distinction is not nearly as clearcut. This has previously been reported in patients identified through newborn screening but not meeting full CF diagnostic criteria, earning the label of CF Screen Positive, Inconclusive Diagnosis (CFSPID) instead. A homologous diagnostic category in adults is named CF Transmembrane Conductance Regulator‐Related Disorder (CFTR‐RD). Methods: Through a retrospective chart review, this study reports on a relatively large adult cohort ( n = 23) that presented to pulmonology clinic at a single center with intermediate or positive sweat chloride tests but non‐diagnostic full CFTR gene analysis. Results: Median sweat chloride result was 48 mmol/L, and a majority of the cohort had chronic lung disease with atypical pathogens on sputum culture, including Pseudomonas aeruginosa, non‐tuberculous Mycobacteria, Acinetobacter species, amongst others. Conclusions: This clinical picture suggests CFTR dysfunction or similar mechanism in the absence of an identified genetic cause. Alternate chloride channels and their respective genes or candidates of genetic modifiers to the CF‐phenotype could be targets of further research in this cohort or similar patients. Such genetic modifiers include loci that have been implicated in inflammation, the CFTR interactome, and/or co‐/post‐translational modification of CFTR.Keywords
This publication has 20 references indexed in Scilit:
- ECFS standards of care on CFTR-related disorders: Towards a comprehensive program for affected individualsJournal of Cystic Fibrosis, 2024
- Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)The Lancet Respiratory Medicine, 2023
- When CFSPID becomes CFJournal of Cystic Fibrosis, 2022
- Perspectives on the translation of in-vitro studies to precision medicine in Cystic FibrosisEBioMedicine, 2021
- Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)Journal of Cystic Fibrosis, 2021
- Adult Patients With BronchiectasisChest, 2017
- Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosisNature Communications, 2015
- Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosisPediatric Pulmonology, 2010
- Diagnosis of Cystic Fibrosis by Sweat Testing: Age-Specific Reference IntervalsThe Journal of Pediatrics, 2008
- The TNFα receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosisHuman Genetics, 2006